Regencell Bioscience Holdings Limited RGC
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.46M | 2.46M | 675.60K | 675.60K | 735.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.67M | 2.67M | 896.10K | 896.10K | 988.90K |
| Operating Income | -2.67M | -2.67M | -896.10K | -896.10K | -988.90K |
| Income Before Tax | -2.66M | -2.66M | -865.30K | -865.30K | -926.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.66M | -2.66M | -865.30K | -865.30K | -926.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.66M | -2.66M | -865.30K | -865.30K | -926.80K |
| EBIT | -2.67M | -2.67M | -896.10K | -896.10K | -988.90K |
| EBITDA | -2.65M | -2.65M | -876.70K | -819.60K | -963.00K |
| EPS Basic | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 494.49M | 494.49M | 494.49M | 494.49M | 494.49M |
| Average Diluted Shares Outstanding | 494.49M | 494.49M | 494.49M | 494.49M | 494.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |